Livestream Preview | eCOA Trends in the CNS Field and the Value of Rater Training

Source: EClinCloud. Author: EClinCloud.

Live trailer
Livestream Preview
With rapid scientific and technological development and ongoing technological innovation, new treatments, assessment tools, and research advances continue to emerge in the central nervous system (CNS) field, placing higher demands on raters' professional capabilities and knowledge base.
To keep pace with these developments and raise the professional proficiency of raters across the industry, on January 29, 2024, from 19:00 to 20:00, EClinCloud and the CMAC DCT Alliance will jointly host the online livestream "eCOA Trends in the CNS Field and the Value of Rater Training". During the livestream, Su Quanyu, Co-Founder and Chief Commercial Officer of EClinCloud, will examine the latest eCOA trends in the CNS field and the innovation and application of rater training in the industry from a forward-looking perspective, and engage in interactive discussions with industry peers to jointly advance the development and progress of the industry.
Speaker
Su Quanyu
Co-Founder and Chief Commercial Officer, EClinCloud
He has extensive commercial and clinical project management experience across CROs and biotech companies, is a pioneer and practitioner in clinical trial digitalization, and is dedicated to advancing the industry's digital transformation.

Scan the QR code on the poster below to register for the livestream.

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interoperable all-in-one clinical trial cloud platform (across technology products and solutions including eCOA, CTMS, eTMF, EDC, RTSM, and RM, offering solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across different therapeutic areas (including CNS and ophthalmology). Combining frontier technology with life science data, it aims to build a globally leading "patient-centric" SaaS cloud platform supporting clinical evidence, helping domestic and international pharmaceutical companies and research institutions improve research and development efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.



